touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial’ (Abstract number: 1332) was presented at the ACR Convergence, 5-9 November.
- Could you give us an overview of the symptoms that negatively impact health-related quality of life in psoriatic arthritis (PsA)? (0:19)
- Why was it important to validate the PROMIS-29 profile in patients with active psoriatic arthritis? (0:52)
- What did the DISCOVER-1 analysis teach us about the impact of guselkumab on joint and skin clinical manifestations of PsA? (1:55)
- Could you tell us a little about the objectives and findings from this current analysis? (2:50)
- What will be the likely role of guselkumab in the treatment paradigm for PsA? (4:22)
Disclosures: Dr Ana-Orbai has acted as a consultant for Eli Lilly, Novartis, Janssen, Pfizer and UCB, and received grant/ research support from AbbVie, Eli Lilly, Celgene, Janssen and Horizon.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Psoriatic Arthritis
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, […]
Laure Gossec, ACR 2022: Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices. This information is brought to you by Touch […]
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!